Protein Linked to Tumor Cells' Metabolism and Immune Evasion

The activity level of regulators in tumors anticipated patients’ outcomes after receiving immunotherapy, stated study.

A promising target for anti-cancer treatments discovered depletes tumors of energy and boosts the body’s immune response against them.

Tumor cells typically alter their energy metabolism and increase glucose uptake to support their rapid division and spread. This limits glucose availability for immune cells and therefore dampens the body’s anti-cancer immune response.

Ampullary Cancer Causes Symptoms Diagnosis Treatment
Ampullary cancer is a rare cancer of the ampulla of Vater that connects the common bile duct and pancreatic duct to the small intestine. Symptoms of ampullary cancer include jaundice, weight loss.

‘A simple biomarker predicts response/non-response to immunotherapy, and supports ESRRA (Estrogen Related Receptor Alpha) as a therapeutic target.’

By searching for proteins that both regulate the metabolism of cancer cells and affect immune cells in tumors, a team led by investigators at Massachusetts General Hospital (MGH) recently identified a potential target for therapies that could simultaneously drain tumors of energy and boost the immune response against them.

For the research, which is published in Cancer Discovery, Keith T. Flaherty, MD, the director of Clinical Research at the MGH Cancer Center and a professor of medicine at Harvard Medical School, and his colleagues developed a new computational tool called BipotentR that can identify targets that block immune activation and also stimulate a second user-defined pathway (in this case, metabolism).

Cancer Immunotherapy Resistance

When applied to gene expression data from patients with cancer who were treated with immunotherapy, as well as from cell lines and animal models, the tool identified 38 cancer cell–specific immune-metabolic regulators.

The topmost identified regulator, ESRRA (Estrogen Related Receptor Alpha), was activated in immunotherapy-resistant tumors of many types. Inhibiting ESRAA killed tumors by suppressing energy metabolism and activating two immune mechanisms involving different types of immune cells.

Test Your Knowledge on Liver Cancer
Primary hepatocellular carcinoma is a cancer that starts in the liver. The liver is the largest organ in the body situated in the upper right quadrant of the abdomen. The liver is also a common site for cancer deposits (metastases) from other organs. This is referred to as secondary liver cancer and is more common than primary liver cancer.

ESRRA inhibition was safe when tested in mice, and its effects on energy metabolism were focused on cancer cells.

The scientists also demonstrated that BipotentR can be applied to other survival mechanisms used by cancer cells, such as their ability to promote blood vessel formation to increase their blood supply.